Colon Cancer Clinical Trial
— ACBCOfficial title:
Acute Colon Resection Versus Bridge to Colon Surgery With Stent or Stoma: a Prospective Cohort Study
P) patients with acute obstructive colon cancer I) resection or bridge to surgery with stent or stoma C) emergency procedure O ) morbidity and mortality within 30 days, 90 day mortality and 3 & 5 years overall survival
Status | Recruiting |
Enrollment | 1000 |
Est. completion date | December 31, 2031 |
Est. primary completion date | December 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility | Inclusion Criteria: - Age >18 years - Symptomatic large bowel obstruction requiring acute intervention - CT-verified colon obstruction due to colon cancer independent of presence of metastases - Informed consent Exclusion Criteria: - Colonic perforation or bleeding - Colonic obstruction of other origin than colon cancer - Palliative situation |
Country | Name | City | State |
---|---|---|---|
Sweden | Göteborg University | Göteborg |
Lead Sponsor | Collaborator |
---|---|
Skane University Hospital | Göteborg University |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of patients with 30-day severe morbidity | Clavien-Dindo >3 within 30 days postop | 30 days | |
Primary | Overall survival after 3 years | survival unspecified | 3 years | |
Primary | Number of patients with 30 day mortality | death within 30 days | 30 days | |
Primary | Overall survival after 5 years | survival unspecified | 5 years | |
Primary | Number of patients with 90 day mortality | death within 90 days | 90 days | |
Secondary | Number of patients with locally radical resections | resections regarded as R0 | 90 days | |
Secondary | Number of examined mesenteric lymph nodes | lymph nodes examined by pathologist | 90 days | |
Secondary | Proportion of patients receiving neoadjuvant or adjuvant treatment | patients receiveing chemotherapy | 1 year | |
Secondary | Proportion of patients with stomas after 3 years | patients with bowel continuity without stome | 3 years | |
Secondary | Recurrence rate after 3 after years | relapse within 3 years | 3 years | |
Secondary | Disease-free survival after 3 years | survival without disease relapse after 3 years | 3 years | |
Secondary | Proportion of patients not being subjected to resection of initially decompressed | patients not proceeding to resection | 90 days | |
Secondary | bridging interval | interval between stenting or stoma and resection | 90 days | |
Secondary | Number of stent complications (perforations, migration, bleeding, success rate etc) | complications in stent group | 90 days | |
Secondary | Number of stoma complications | complications in stoma group | 90 days | |
Secondary | Morbidity and survival and impact of tumour location | 30 day morbidity and mortality depending on tumour location i.e. right or left colon | 5 years | |
Secondary | Number of laparoscopic resections | numbers of laparoscopic vs open resections | 90 days | |
Secondary | Number of primary anastomosis | number of primary anastomosis in the Bridge to Surgery vs up front resection group | 90 days | |
Secondary | Number of stomas after resection and type of stoma | number of stomas in Bridge to Surgery vs up front resection group | 90 days | |
Secondary | total hospital stay in days | days in hospital in Bridge to Surgery vs up front resection | 90 days | |
Secondary | colorectal surgeon performing resectional surgery | qualified colorectal surgeon, general surgeon or resident performing resectional surgery | 90 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT03457454 -
Reducing Rural Colon Cancer Disparities
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04088955 -
A Digimed Oncology PharmacoTherapy Registry
|
||
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Terminated |
NCT01347645 -
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03390907 -
Hybrid APC Assisted EMR for Large Colon Polyps
|
N/A | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT04079478 -
The AID Study: Artificial Intelligence for Colorectal Adenoma Detection
|
||
Active, not recruiting |
NCT04057274 -
Acute Effect of modeRate-intensity aerOBIc Exercise on Colon Cancer Cell Growth
|
N/A | |
Recruiting |
NCT03190941 -
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05147545 -
Impact of Exercise and Hyperlipidic Meal on Free Circulating DNA in Patients With Metastatic Colonic Cancer and Healthy Subjects
|
N/A | |
Recruiting |
NCT05026268 -
The Laparoscopic Right Colectomy With Intracoroporeal Anastomosis
|
N/A | |
Not yet recruiting |
NCT03277235 -
Effect of a Resilience Model-Based Care Plan in Newly Diagnosed Colorectal Cancer Patients
|
N/A | |
Active, not recruiting |
NCT02959541 -
PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer
|
N/A | |
Active, not recruiting |
NCT02730702 -
Colon Cancer Risk-stratification Via Optical Analysis of Rectal Ultrastructure
|
||
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A | |
Recruiting |
NCT02577627 -
Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOC
|
N/A | |
Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 | |
Recruiting |
NCT02526836 -
Complete Mesocolic Excision With Central Vessel Ligation Compared With Conventional Surgery for Colon Cancer
|
Phase 2/Phase 3 |